Rosen Law Firm Investigates Disc Medicine, Inc. Securities Claims
Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. The investigation follows allegations that the company may have issued materially misleading business information to the investing public.
Rosen Law Firm is continuing its investigation into potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON). The investigation stems from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
The core of the investigation relates to a Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) on February 13, 2026. The FDA stated it could not approve Disc Medicine's new drug application (NDA) for its bitopertin program due to uncertainties requiring additional evidence.
Following this news, Disc Medicine's stock price experienced a 22% decline on February 13, 2026. Rosen Law Firm is preparing a class action lawsuit to seek recovery for investor losses.
Investors who purchased Disc Medicine securities and believe they have suffered losses are encouraged to contact Rosen Law Firm for information regarding the class action. The firm specializes in securities class actions and represents investors worldwide.